Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on Oncopeptides' Q2 report.</li><li>Sales amounted to SEK31.1m, an increase of 23 percent versus Q1 2026 and 62 percent versus Q2 2025.</li><li>Germany and Italy carried the growth, while Spain improved late in the quarter despite an ongoing doctors' strike, and Greece contributed nothing after a budget-driven order pause.</li></ul>

Redeye comments on Oncopeptides' Q2 report.Sales amounted to SEK31.1m, an increase of 23 percent versus Q1 2026 and 62 percent versus Q2 2025.Germany and Italy carried the growth, while Spain improved late in the quarter despite an ongoing doctors' strike, and Greece contributed nothing after a budget-driven order pause.

Oncopeptides (Q2 Update): Growth Continues, with CEE Region Unlocked